For instance, the reduction of TET2 enzyme levels by promoter methylation in absence of TET2 mutation was reported recently in low-grade diffuse astrocytomas, suggesting that this represents an additional pathomechanism in IDH1- and IDH2-mutated low-grade gliomas [48]. The gene discussed is IDH2; the disease is central nervous system cancer.